文献速递淋巴瘤

原发纵隔大B细胞淋巴瘤的遗传学特征:发病机制与患者结局

Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
PubMed 文献 · J Clin Oncol · 2023-12-06

该研究对340例初治原发纵隔大B细胞淋巴瘤(PMBCL)患者进行全基因组、全外显子和靶向测序,发现p53通路常见破坏及新的免疫逃逸相关结构变异,多变量分析识别出6个具有显著预后影响的遗传病变,其中CD58突变与更差的无进展生存(PFS)和总生存(OS)相关,DUSP2突变则与持久缓解和更长生存相关。

要点

  • CD58突变(31%)与更差PFS独立相关(HR 2.52,95%CI 1.50-4.21;P<.001),与更差OS相关(HR 2.33,95%CI 1.14-4.76;P=.02)。
  • DUSP2突变(24%)与持久缓解相关(PFS HR 0.2,95%CI 0.07-0.55;P=.002)和更长OS相关(HR 0.11,95%CI 0.01-0.78;P=.028)。
  • CD58突变的不良预后意义主要在非强化方案治疗患者中观察到,提示剂量强化可能部分减轻该高危标志物的影响。

核心结论

  • 该大规模基因组学研究识别了PMBCL新的治疗靶点和用于精细风险分层的遗传病变。
  • DUSP2和CD58突变分析可能指导在R-CHOP与剂量调整的EPOCH-R之间的治疗决策。

研究设计与样本

  • 对340例既往未治疗的PMBCL患者样本进行全基因组测序(n=20)、全外显子测序(n=78)和靶向测序(n=308)。
  • 采用多变量Cox回归模型识别统计学显著的预后变量,并通过L1/L2正则化回归确认。

主要发现

  • 全基因组测序显示p53通路常见破坏,TP53相关基因(TP63、TP73和WWOX)存在非冗余体细胞结构变异,并发现促进免疫逃逸的新结构变异(DOCK8和CD83)。
  • 整合突变和拷贝数数据扩展了已知PMBCL改变谱(如ARID1A、P2RY8和PLXNC1),并揭示了表观遗传/染色质修饰因子的先前未认识作用。
  • 多变量分析识别出6个具有显著预后影响的遗传病变。
  • CD58突变(31%)与更差PFS最强相关(HR 2.52,95%CI 1.50-4.21;P<.001),与更差OS相关(HR 2.33,95%CI 1.14-4.76;P=.02);IPI高危且CD58突变患者5年PFS和OS分别为41%和58%。
  • DUSP2突变患者(24%)显示持久缓解(PFS HR 0.2,95%CI 0.07-0.55;P=.002)和延长OS(HR 0.11,95%CI 0.01-0.78;P=.028);接受CHOP类治疗时5年PFS和OS分别为93%和98%。

临床怎么用

  • 作者认为,DUSP2和CD58突变分析可能指导在利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP)与剂量调整的依托泊苷、泼尼松、长春新碱、环磷酰胺、多柔比星和利妥昔单抗(DA-EPOCH-R)之间的治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Primary mediastinal large B-cell lymphoma (PMBCL) is a rare aggressive lymphoma predominantly affecting young female patients. Large-scale genomic investigations and genetic markers for risk stratification are lacking. PATIENTS AND METHODS: To elucidate the full spectrum of genomic alterations, samples from 340 patients with previously untreated PMBCL were investigated by whole-genome (n = 20), whole-exome (n = 78), and targeted (n = 308) sequencing. Statistically significant prognostic variables were identified using a multivariable Cox regression model and confirmed by L1/L2 regularized regressions. RESULTS: Whole-genome sequencing revealed a commonly disrupted p53 pathway with nonredundant somatic structural variations (SVs) in TP53-related genes (TP63, TP73, and WWOX) and identified novel SVs facilitating immune evasion (DOCK8 and CD83). Integration of mutation and copy-number data expanded the repertoire of known PMBCL alterations (eg, ARID1A, P2RY8, and PLXNC1) with a previously unrecognized role for epigenetic/chromatin modifiers. Multivariable analysis identified six genetic lesions with significant prognostic impact. CD58 mutations (31%) showed the strongest association with worse PFS (hazard ratio [HR], 2.52 [95% CI, 1.50 to 4.21]; P < .001) and overall survival (HR, 2.33 [95% CI, 1.14 to 4.76]; P = .02). IPI high-risk patients with mutated CD58 demonstrated a particularly poor prognosis, with 5-year PFS and OS rates of 41% and 58%, respectively. The adverse prognostic significance of the CD58 mutation status was predominantly observed in patients treated with nonintensified regimens, indicating that dose intensification may, to some extent, mitigate the impact of this high-risk marker. By contrast, DUSP2-mutated patients (24%) displayed durable responses (PFS: HR, 0.2 [95% CI, 0.07 to 0.55]; P = .002) and prolonged OS (HR, 0.11 [95% CI, 0.01 to 0.78]; P = .028). Upon CHOP-like treatment, these patients had very favorable outcome, with 5-year PFS and OS rates of 93% and 98%, respectively. CONCLUSION: This large-scale genomic characterization of PMBCL identified novel treatment targets and genetic lesions for refined risk stratification. DUSP2 and CD58 mutation analyses may guide treatment decisions between rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Noerenberg D, Briest F, Hennch C, et al. Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes. J Clin Oncol. 2023. PMID: 38055913. doi:10.1200/JCO.23.01053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。